Company profile: Ensoma
1.1 - Company Overview
Company description
- Provider of one-time in vivo genomic medicine solutions, including the Engenious platform for multi-cellular genome editing to engineer hematopoietic and immune cells via a single outpatient treatment; virus-like particle delivery systems devoid of viral genes with up to 35 kb payloads to minimize immune responses; smart cell therapies for cancer; and integrated tools for gene replacement, editing, endogenous protein therapies, and regulatory elements.
Products and services
- Engenious Platform: Engineers in vivo multi-cellular genome editing, precisely modifying hematopoietic and immune cells in a single outpatient treatment while integrating gene replacement, editing, endogenous protein therapies, and regulatory elements
- Smart Cell Therapies for Cancer: In vivo immune-system editing that architects immune cells to target and attack cancer cells, enabling one-time treatment using precise multi-cellular genome modification
- Virus-Like Particle (VLP) Delivery System: Non-viral carriers devoid of viral genes that minimize immune responses and transport up to 35 kilobases of DNA for in vivo gene modification payloads
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ensoma
Vericel
HQ: United States
Website
- Description: Provider of therapies for cartilage repair and burn care, including MACI for knee cartilage defects using the patient’s own cultured cells on a collagen membrane; Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns covering a large percentage of their body; and NexoBrid, a bromelain-based enzymatic solution for eschar removal in adults with deep partial- and/or full-thickness thermal burns.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vericel company profile →
Vital Therapies
HQ: United States
Website
- Description: Provider of cell-based therapy development for acute liver failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vital Therapies company profile →
Myst Therapeutics
HQ: United States
Website
- Description: Provider of novel broad-spectrum cancer immunotherapy products and adoptive cell therapies for solid tumors, harnessing a patient's own immune system via enriched tumor-derived T cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myst Therapeutics company profile →
BioXyTran
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting stroke, ischemia, and COVID-19 complications. Pipeline includes BXT-25 to deliver oxygen to brain tissue during and after ischemic stroke; ProLectin-M (chewable) and ProLectin-I (IV) for mild to severe COVID-19; ProLectin-A for COVID-19-related ARDS; ProLectin-F for ventilator-induced lung fibrosis; and a galectin antagonist to reduce viral load and modulate immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioXyTran company profile →
Cellular Biomedicine Group
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development focused on immunotherapies for cancers and stem cell therapies for degenerative diseases, utilizing proprietary cell therapy technologies built on thirty years of research and human treatment experience.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellular Biomedicine Group company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ensoma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ensoma
2.2 - Growth funds investing in similar companies to Ensoma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ensoma
4.2 - Public trading comparable groups for Ensoma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →